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Abstract
Background: Human papilloma virus (HPV) has been implicated in the development of a large proportion of
oropharyngeal squamous cell carcinoma (OPSCC). Current techniques used to diagnose HPV etiology require
histopathologic analysis. We aim to investigate the diagnostic accuracy of a new application non-histopathologic
diagnostic tests to help assist diagnosis of HPV-related oropharyngeal tumors.
Methods: Patients with OPSCC with nodal metastasis were consecutively recruited from a multidisciplinary cancer
clinic. Appropriate samples were collected and analyzed. The various tests examined included COBAS® 4800,
Cervista® HR and Genotyping. These tests were compared to p16 staining, which was used as the diagnostic
standard. StataIC 14.2 was used to perform analysis, including sensitivity, specificity and receiver operator
characteristic [ROC] curves.
Results: The COBAS® FNA (area under ROC 0.863) and saliva (area under ROC 0.847) samples performed well in
diagnosing HPV positive and negative tumors. Samples tested with Cervista® did not corroborate p16 status reliably.
We were able to increase the diagnostic yield of the COBAS® FNA samples by applying the results of the saliva test
to negative FNA samples which correctly identified 11 additional p16 positive tumors (area under ROC 0.915).
Conclusion: Surrogate testing for HPV using alternate methods is feasible and closely predicts the results of
standard diagnostic methods. In the future, these could minimize invasive procedures for diagnosing HPV-related
oropharyngeal cancer, but also help to diagnose and treat patients with unknown primaries.
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Background
Human papilloma virus (HPV) infection is linked to the
development of several human malignancies, notably
oropharyngeal squamous cell carcinoma (OPSCC)
within the head and neck region [1, 2]. In fact, OPSCC
has been increasing in prevalence despite decreasing
trends in other common cancers [3], and HPV, particu-
larly subtype 16, is thought to contribute to this trend,
with over 60% of OPSCC expressing HPV DNA or its
markers [1, 4]. HPV related OPSCC has been shown to
affect a younger population and is more likely to present
with advanced nodal disease but early T-staging [5], and
is overall associated with an increased survival rate and
improved overall prognosis [6–8]. However, treatment of
OPSCC can have significant morbidity including, but
not limited to, chronic pain and dysphagia, making it
important for diagnostic tests to be developed and stud-
ied for application in screening purposes. In fact, to this
day there are no widely available or approved diagnostic
tests available to help identify patients at risk of OPSCC
or with presence early OPSCC.
The goal of this study is to identify a diagnostic algorithm
that could be used to predict a patient’s HPV-positivity
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using surrogate markers. These tests were performed on
samples obtained from patients with known OPSCC, as
part of a phase 1 diagnostic test study that will identify pos-
sible candidates for future use in screening. We also explore
a diagnostic algorithm that may help differentiate HPV-
positive from HPV-negative malignancy in the presence of
known nodal metastatic disease.
Methods
This study was approved by the Hamilton Integrated Re-
search Ethics Board. Patients were enrolled from a
multidisciplinary head and neck cancer clinic, where
newly diagnosed biopsy proven OPSCC participants
were recruited into the study from July 2012 to July
2015. Patients were considered eligible if they newly di-
agnosed, histopathologically proven OPSCC with at least
one positive lymph node that could be sampled using
fine needle aspiration biopsy (FNA). All patients were
recruited after signed informed consent.
FNA samples were obtained by senior head and
neck surgeons (MG, BSJ, SA, JEMY) for the purposes
of the study, and saliva samples and oropharyngeal
swabs (tongue base and tonsil) were collected by our
research liaison (LDM). If the patients had not yet
undergone panendoscopy and multiple biopsies in
their work up, FNA was performed intraoperatively at
the time of this procedure in order to minimize pa-
tient discomfort. The technique for FNA sampling
was with multiple passes (greater than 3) into the
palpable node using a 22 gauge needle on a 10 cc
syringe. For lymph nodes that could not be easily
sampled when guided by palpation, ultrasound-guided
FNA was performed at the radiology department at
St-Joseph’s Hospital in Hamilton. Saliva samples and
oropharyngeal swabs collected by our research liaison
(LDM), who counselled the participants to spit into a
test tube container (roughly 1 ml sample obtained)
and collected the swabs by firmly touching both ton-
sils and accessible oropharynx with the applicator
through the oral opening. These samples were then
tested for presence of HPV at the Infections Research
Laboratory at St-Joseph’s Hospital. The saliva, swabs,
and FNA samples were tested for high-risk HPV
Cobas® 4800 (Roche, Basel Switzerland), and the FNA
and swab samples were tested with Cervista® HR and
Cervista® HPV genotyping (Hologic, WI, USA). Re-
sults were compared to p16 staining of the primary
tumor site. Staining for p16 occurred at the immuno-
histochemistry lab, and were considered positive if
greater than 70% of the primary site tissue biopsy
stained for p16. All testers of collected samples were
blinded from cytologic and histopathologic results.
Statistical analysis
StataIC version 14.2 (TX, USA) was used to perform
statistical analyses. Receiver operating characteristics
(ROC) was used to compare the diagnostic accuracy of
the various assays (Cobas® 4800, Cervista HR and HPV
genotype) on each sample collected (saliva, oral swabs,
FNA). ROC analysis was designed as plot of sensitivity
(y-axis) versus 1 minus specificity (x-axis). Results were
coded as categorical variables (i.e. test was either positive
or negative). Sensitivities, specificities and areas under
the ROC were calculated and are reported with 95%
confidence intervals (95% CI).
Results
Of 91 patients enrolled in the study, seventy-seven pa-
tients met our inclusion criteria. Seventy participants
were male and seven were female. The mean age was
59.4 (SD 9.6, range 40 to 80). There were 66 HPV posi-
tive tumors and 11 were HPV negative as confirmed by
p16 positivity (HPV positivity 85.7%). Several samples
lacked sufficient volume for testing with COBAS® (FNA
6, BOT 1, Saliva 3). As well, Cervista® HR and Genotype
was only applied to samples from 43 participants due to
limitations related to cost redistribution favoring other
tests with higher diagnostic yield. Data from 37 partici-
pants met inclusion criteria for our analysis.
Results are summarized in Table 1. COBAS® assays
performed best when testing material collected by
FNA and saliva. COBAS® testing of FNA was 86%
sensitive [ROC area 0.86 (95% CI 0.76–0.93)] and sal-
iva testing being 100% sensitive [ROC area 0.85 (95%
Table 1 Assay performance by type of sample
Test Sample type Sensitivity Specificity Area under curve (ROC)
Cobas® DNA FNA 91% 82% 0.86 (95% CI 0.75–0.93)
OP Swab 91% 36% 0.63 (95% CI 0.55–0.75)
Saliva 100% 69% 0.85 (95% CI 0.75–0.92)
Cervista® HR FNA 0% 90% 0.45 (95% CI 0.26–0.62)
OP swab 100% 33% 0.67 (95% CI 0.45–0.86)
Cervista® HPV Genotype FNA 0% 86% 0.43 (95% CI 0.25–0.61)
OP Swab 100% 14% 0.57 (95% CI 0.34–0.77)
HPV Human papilloma virus, DNA Deoxyribonucleic acid, FNA Fine needle aspirate, OP Oropharyngeal
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CI 0.75–0.92)]. These samples outperformed those
collected by swabbing of the oropharynx (OP swab)
(ROC area 0.63; 95% CI 0.52–0.74). Cervista® HR and
Genotyping assays was not successful in correctly
identifying HPV in samples collected by FNA and
oropharyngeal swab. Only Cervista® HR oropharyngeal
swabs performed better than a coin toss with an ROC
area of 0.67 (95% CI 0.45–0.86).
In the second part of the analysis, we studied combi-
nations of these diagnostic tests in order to develop an
algorithm that most accurately identified HPV positive
tumors. The highest performing tests (ROC greater than
0.8) were tested in a forward stepwise fashion to formu-
late an algorithm that best predicted HPV status of the
primary tumor. Fine needle aspirate Cobas® DNA sam-
ples were used as the primary test followed by Cobas®
DNA saliva analysis of saliva samples in patients testing
negative for HPV with the FNA samples. This combin-
ation had a sensitivity and specificity of 91 and 92% re-
spectively, and an area under the ROC of 0.92 (95% CI
0.83–0.97, see Fig. 1). This combination correctly classi-
fied an additional 11 participants.
Discussion
This study shows promising results for several commer-
cially available tests for diagnosis of HPV-related malig-
nancy of the oropharynx. In fact, we were able to show
that the Cobas® 4800 system was most sensitive to HPV
positivity when testing FNA and saliva samples. As well,
we were able to formulate a simple diagnostic algorithm
consisting of FNA testing with COBAS® 4800 on FNA
samples followed by Cobas® 4800 assay of saliva samples
for those initially testing negative. This simple algorithm
yielded an excellent diagnostic accuracy (AUC 0.92).
This study has identified a test that correctly diag-
nosed HPV positive and negative patients in 92% of
HPV-related OPSCC. In fact, the Cobas® 4800 assay
when used sequentially on FNA samples followed by sal-
iva sample. This is the first study to our knowledge to
assess multiple genetic and molecular tests on various
biologic samples obtained from the oropharynx and
nodal disease, in a population where HPV positivity can
be confirmed by gold standard oncologic testing of pri-
mary tumor site.
The diagnostic algorithm we were able to develop is of
particular interest in the setting of cancers of unknown
primary (CUP). CUPs are defined as the presence of ma-
lignancy in one or more lymph nodes in the absence of
a primary site malignancy [9]. Although these malignan-
cies present a diagnostic challenge, literature suggests
that CUP is related to HPV-infection in a third of cases
or more [10–12]. The proposed mechanism for CUP of
the head and neck is that the presence of cancer may
exist in biopsied areas such as tonsils and may never be
identified due to a small foci of cancer that may be
missed on pathological assessment, or may result from
primary tumor site regression [13] after nodal metastasis
has already occurred. Due to the improved prognosis of
HPV-related tumors, as well as the future direction of
de-escalation therapy [14, 15] in this patient population,
establishing a way to correctly identify HPV-related CUP
is essential. Furthermore, given the fact that HPV posi-
tivity strongly suggests involvement of the oropharynx,
knowledge that a cancerous lymph node contains HPV
related disease may both aid in the search of occult pri-
maries and help tailor treatment of these cancers.
The head and neck literature has demonstrated the
use of assays validated on genital or cervical specimens
[16], as well as the use of cytologic brushes of
pharyngeal mucosa to confirm oncogenic HPV infection
[17, 18]. However, none of these are yet approved for
use in determining HPV status in the oropharynx. The
use of the swab and saliva-based tests may offer another
way to determine high-risk HPV infection.
Limitations of our study include a small sample size
due to the fact that this is a single center study, which
limits the overall generalizability of the results. However,
the goal of this project is of an exploratory nature, there-
fore the results can be used for sample size calculations
as well as guide future research on this topic. Another
limitation of our study was due to limited resources, as
we were not able to complete testing of Cervista® HR
and HPV genotyping on all the samples collected, This
limits our ability to determine the diagnostic accuracy of
this assay on samples obtained in patients with OPSCC.
As well, our analysis was limited by insufficient sam-
ple material available for testing, particularly for the
Cervista® assays. One case (COBAS® testing of FNA sam-
ple) yielded an indeterminate result due to contamination
with blood (see Table 2). Due to these limitations, we
recommend further studies to better determine the
Fig. 1 Comparison COBAS® FNA alone and FNA then Saliva
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diagnostic accuracy of the tests evaluated here. Finally, the
prevalence of HPV positive patients was high in our study
(85.7%), likely owing to the inclusion requirement of nodal
disease at presentation. However, this should not impact
the results we reported, since sensitivity and specificity are
not impacted by disease prevalence. However, a larger
sample size would have likely allowed us to narrow the
confidence intervals around our ROC areas, improving
the precision of the estimates.
Conclusion
This study shows that it is possible and feasible to ac-
curately diagnose oncogenic HPV infection of the oro-
pharynx through non-invasive surrogate testing. We
recommend future studies to focus on the validation of
such diagnostic tests on the general population, as well
as on patients with CUP for improved risk stratification
in these patient groups.
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